Compare NCNO & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | ATRC |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2022 | 2005 |
| Metric | NCNO | ATRC |
|---|---|---|
| Price | $19.56 | $59.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | $26.07 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 2.3M | 1.0M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.15 | 74.74 |
| EPS | 0.18 | 0.18 |
| Revenue | ★ $594,781,000.00 | $201,630,000.00 |
| Revenue This Year | $9.53 | $15.27 |
| Revenue Next Year | $8.97 | $12.21 |
| P/E Ratio | ★ $110.94 | $337.61 |
| Revenue Growth | 10.01 | ★ 15.40 |
| 52 Week Low | $13.80 | $25.36 |
| 52 Week High | $28.20 | $61.70 |
| Indicator | NCNO | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 71.81 |
| Support Level | $19.14 | $26.95 |
| Resistance Level | $19.71 | N/A |
| Average True Range (ATR) | 0.85 | 2.13 |
| MACD | -0.41 | 0.01 |
| Stochastic Oscillator | 13.55 | 73.31 |
Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.